| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Molecular Biology (Z-D.X., L.O., N.-S.L., J.J.R., Y.F.-Y.) Beckman Research Institute of the City of Hope and Department of Urology (L.O., M.H.K.), City of Hope Medical Center, Duarte, California 91010; and Department of Biochemistry, Physiology, and Medicine (S.M.), Loma Linda University, Jerry L. Pettis Veterans Affairs Medical Center, Loma Linda, California 92357
Address all correspondence and requests for reprints to: Yoko Fujita-Yamaguchi, Ph.D., Department of Molecular Biology, Beckman Research Institute of the City of Hope, 1450 East Duarte Road, Duarte, California 91010. E-mail: yyamaguchi{at}coh.org
Insulin-like growth factor (IGF)-II plays an important role in fetal
growth and development. IGFs are potent mitogens for a variety of
cancer cells. A paracrine/autocrine role of IGF-II in the growth of
breast and prostate cancer cells has been suggested. To test the role
of IGF-II in cancer cell growth, hammerhead ribozymes targeted to human
IGF-II RNA were constructed. Single (R)- and double (RR)-ribozymes were
catalytically active in vitro whereas mutant ribozymes
(M or MM) did not cleave IGF-II RNA. RR was more active than R. In
human prostate cancer PC-3 cells, both R and RR similarly suppressed
IGF-II messenger RNA (mRNA) levels (
40%) compared with the level in
parental or M-expressing PC-3 cells. Polymerase II and III
promoter-driven R similarly suppressed IGF-II mRNA levels. Suppression
of IGF-II mRNA levels by R was associated with suppression of IGF-II
protein levels. R- (or RR-) expressing PC-3 cells did not grow under
serum-starved conditions and showed prolonged doubling times in the
presence of 10% FCS compared with those of parental or M-expressing
cells. These results substantiated that IGF-II plays a critical role in
prostate cancer cell growth.
This article has been cited by other articles:
![]() |
L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Jiang, D. Grimshaw, J. Lane, T. A. Martin, R. Abounder, J. Laterra, and R. E. Mansel A Hammerhead Ribozyme Suppresses Expression of Hepatocyte Growth Factor/Scatter Factor Receptor c-MET and Reduces Migration and Invasiveness of Breast Cancer Cells Clin. Cancer Res., August 1, 2001; 7(8): 2555 - 2562. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Teng, N. Fukuda, W.-Y. Hu, M. Nakayama, H. Kishioka, and K. Kanmatsuse DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-{beta}1 mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats Cardiovasc Res, October 1, 2000; 48(1): 138 - 147. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Svaren, T. Ehrig, S. A. Abdulkadir, M. U. Ehrengruber, M. A. Watson, and J. Milbrandt EGR1 Target Genes in Prostate Carcinoma Cells Identified by Microarray Analysis J. Biol. Chem., December 1, 2000; 275(49): 38524 - 38531. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |